Progression-free survival was significantly greater in the durvalumab plus bevacizumab group compared to placebo. 2. Common treatment-related adverse events included hypertension and anemia. Evidence ...

Topline results were announced from a phase 3 trial evaluating durvalumab in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) ...

MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as ...

Discover a study that found that the combination of durvalumab and tremelimumab with concurrent radiotherapy is a feasible ...

AstraZeneca Pharma India gets CDSCO nod for durvalumab to treat LS-SCLC: Our Bureau, Bengaluru Monday, March 10, 2025, 15:30 Hrs [IST] AstraZeneca Pharma India, received a Central ...

The time of day of immunotherapy infusions does appear to affect patient outcomes. But convincing the wider oncology ...

With this approval, durvalumab can now be used for treating patients with limited-stage small cell lung cancer (LS-SCLC) ...

EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...

AstraZeneca Pharma India Ltd has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute the cancer treatment drug Durvalumab in India. This approval ...

AstraZeneca Pharma India has announced that the Company has received permission from the CentralDrugs Standard Control ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...